- Georgiamune to ship preclinical solid tumor drug to Menarini in deal up to $1.1 billionGeorgiamune, a small biotech based in Maryland, announced that it will supply its preclinical solid tumor candidate to Menarini, a family‑owned pharmaceutical company in Italy. The agreement is st…
- Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T programRoche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…